The Fasting II Study

Diabetes Clinical Trial

Official title:

Preparatory Study to Determine Which Risk Markers May be Reduced by Fasting and Should be Evaluated in a Future Randomized Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01792986
• Other study ID #: 1024469
• Status: Completed
• Phase: N/A
• First received: February 12, 2013
• Last updated: August 1, 2013
• Start date: February 2013

Study information

• Verified date: July 2013
• Source: Intermountain Health Care, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This study will determine whether an intensive fasting protocol alters hemoglobin A1c measurements or other markers of metabolic and cardiovascular risk by performing a 5-week clinical trial of fasting among 12 pre-diabetic individuals or diabetics whose disease is controlled by diet. Participants will undergo a 5-week intervention of once-per-week 24-hour water-only fasting, including at baseline and at the end of the week for each week of the study (a total of 6 24-hour fasts).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. primary completion date: June 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 30 Years to 69 Years

Eligibility

Inclusion Criteria:

1. Male or non-pregnant female, =30 and <70 years of age.

2. Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures.

3. Prior evidence of pre-diabetic state, with one of the following:

1. Pre-diabetic with a measured HbA1c =6.0% or fasting glucose >100 mg/dL without a clinical diabetes diagnosis

2. Clinically-diagnosed type II diabetic with HbA1c =6.0% or fasting glucose =110 mg/dL and whose disease is controlled by diet alone.

4. Evidence of metabolic syndrome by having at least 3 of the following 5 criteria:

1. Fasting glucose level >100 mg/dL.

2. Blood pressure =135 mmHg systolic or =85 mmHg diastolic, or use of an antihypertensive medication.

3. High-density lipoprotein cholesterol <40 mg/dL in males or <50 mg/dL in females.

4. Triglycerides =150 mg/dL or use of a cholesterol-lowering medication.

5. Waist circumference >40 inches (102 cm) for males or >35 inches (88 cm) for females (or body mass index >25 kg/m2).

Exclusion Criteria:

1. Pregnant and/or lactating women and women of child bearing potential who are not using acceptable means of contraception. Women of childbearing potential must be using adequate measures of contraception (as determined by the Principal Investigator) to avoid pregnancy and should be highly unlikely to conceive during the study period. Women of childbearing potential must have a negative pregnancy test at screen.

2. Diabetics taking any of the following anti-diabetic medications: insulin, metformin, thiazolidinediones, sulfonylureas, alpha-glucosidase inhibitors, meglitinides, or incretins.

3. Prior experience with fasting more than once per month (for 20 hours or more), on average during the last year.

4. Very low BMI (<18.5 kg/m2) or high BMI (>40 kg/m2).

5. Individuals who are nutritionally compromised, as assessed by the Principal Investigator.

6. Any immunodeficiency or prior solid organ transplantation or renal disease.

7. Participation in any other clinical trials involving investigational or marketed products within 30 days prior to entry in the study.

8. Other conditions that in the opinion of the Principal Investigator may increase risk to the subject and/or compromise the quality of the clinical trial.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Diabetes
• Metabolic Diseases

Intervention

Behavioral:
• water-only 24-hour fasting

Locations

Country	Name	City	State
United States	Intermountain Medical Center	Murray	Utah
United States	Intermountain Medical Center	Salt Lake City	Utah

Sponsors (2)

Lead Sponsor	Collaborator
Intermountain Health Care, Inc.	Intermountain Research and Medical Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in mean hemoglobin A1c level between baseline and the end of the fifth week.		5 weeks	No